Calcitonin gene-related peptide can be selected as a predictive biomarker on progression and prognosis of knee osteoarthritis
The purpose of this study was to examine calcitonin gene-related peptide (CGRP) concentrations in serum and synovial fluid of patients with primary knee osteoarthritis (OA) and healthy controls and to explore their relationship with clinical and radiographic severity of OA.
Sixty-five patients with primary knee OA and 21 healthy controls were recruited. CGRP concentrations in the serum and synovial fluid were measured using enzyme-linked immunosorbent assays. The radiographic severity of OA was evaluated using the Kellgren and Lawrence (KL) classification. The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) was used to assess pain, stiffness and physical function.
Serum and synovial fluid CGRP concentrations tended to be higher with the increase in KL grades (r = 0.565 and r = 0.441, P < 0.001, respectively), and were significantly positively correlated with KL grades, total WOMAC score and each subscale (pain, stiffness and physical function).
The result demonstrated that CGRP in serum and synovial fluid was related to progressive joint damage in knee OA. CGRP can be selected as a biomarker for monitoring disease severity and could be a predictive role on prognosis and progression of knee OA.
KeywordsCalcitonin gene-related peptide Knee osteoarthritis Serum Synovial fluid
- 8.Bellucci F, Meini S, Cucchi P, Catalani C, Nizzardo A, Riva A, Guidelli GM, Ferrata P, Fioravanti A, Maggi CA (2013) Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis. Osteoarthritis Cartilage 21:1774–1780PubMedCrossRefGoogle Scholar
- 12.Saito T, Koshino T (2000) Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin Orthop Relat Res (376):172–182Google Scholar
- 15.Hernanz A, Medina S, de Miguel E, Martı́n-Mola E (2003) Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept 115:19–24PubMedCrossRefGoogle Scholar
- 21.Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
- 24.Ayral X, Pickering E, Woodworth T, Mackillop N, Dougados M (2005) Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis—results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 13:361–367PubMedCrossRefGoogle Scholar
- 26.Zhou SJ, Sun ZX, Liu J (2013) Neopterin concentrations in synovial fluid may reflect disease severity in patients with osteoarthritis. Scand J Clin Lab Invest 73:344-348Google Scholar
- 28.Scrivo R, Conigliaro P, Riccieri V, Di Franco M, Alessandri C, Spadaro A, Perricone R, Valesini G (2015) Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin Exp Immunol 179:300–308PubMedCrossRefGoogle Scholar
- 30.Honsawek S, Yuktanandana P, Tanavalee A, Chirathaworn C, Anomasiri W, Udomsinprasert W, Saetan N, Suantawee T, Tantavisut S (2012) Plasma and synovial fluid connective tissue growth factor levels are correlated with disease severity in patients with knee osteoarthritis. Biomarkers 17:303–308PubMedCrossRefGoogle Scholar
- 33.Dallos A, Kiss M, Polyanka H, Dobozy A, Kemeny L, Husz S (2006) Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 40:251–263PubMedCrossRefGoogle Scholar
- 38.Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, Nelson J, Gaynor B, Xu J, Wang XF, Lynch RA, Li B, McCarty D, Oskins JL, Lin C, Johnson KW, Chambers MG (2014) Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage 22:578–585PubMedCrossRefGoogle Scholar